xofigo Drug Patent Profile
✉ Email this page to a colleague
When do Xofigo patents expire, and what generic alternatives are available?
Xofigo is a drug marketed by Bayer Hlthcare and is included in one NDA.
The generic ingredient in XOFIGO is radium ra-223 dichloride. One supplier is listed for this compound. Additional details are available on the radium ra-223 dichloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for xofigo?
- What are the global sales for xofigo?
- What is Average Wholesale Price for xofigo?
Summary for xofigo
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 30 |
Drug Prices: | Drug price information for xofigo |
What excipients (inactive ingredients) are in xofigo? | xofigo excipients list |
DailyMed Link: | xofigo at DailyMed |
![xofigo drug patent expirations Drug patent expirations by year for xofigo](/p/graph/s/t/xofigo-patent-expirations.png)
![Drug Prices for xofigo](/p/graph/drug-price/xofigo.png)
Recent Clinical Trials for xofigo
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
GenesisCare USA | Phase 3 |
Bayer | Phase 4 |
Tulane University | Phase 3 |
Pharmacology for xofigo
Drug Class | Radioactive alpha-Particle Emitting Therapeutic Agent |
Mechanism of Action | alpha-Particle Emitting Activity |
US Patents and Regulatory Information for xofigo
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bayer Hlthcare | XOFIGO | radium ra-223 dichloride | SOLUTION;INTRAVENOUS | 203971-001 | May 15, 2013 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for xofigo
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bayer Hlthcare | XOFIGO | radium ra-223 dichloride | SOLUTION;INTRAVENOUS | 203971-001 | May 15, 2013 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for xofigo
See the table below for patents covering xofigo around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Norway | 990001 | ⤷ Sign Up | |
Israel | 144135 | ⤷ Sign Up | |
China | 1767078 | ⤷ Sign Up | |
South Africa | 200105431 | The preparation and use of radium-233 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning. | ⤷ Sign Up |
Brazil | 9916768 | ⤷ Sign Up | |
Turkey | 200102707 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for xofigo
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1140212 | 122014000052 | Germany | ⤷ Sign Up | PRODUCT NAME: RADIUM-223-SALZ, INSBESONDERE RADIUM-223-DICHLORID; REGISTRATION NO/DATE: EU/1/13/873 20131113 |
1140212 | 1490034-4 | Sweden | ⤷ Sign Up | PRODUCT NAME: RADIUM-223; REG. NO/DATE: EU/1/13/873 20131113 |
1140212 | 507 | Finland | ⤷ Sign Up | |
1140212 | CA 2014 00027 | Denmark | ⤷ Sign Up | PRODUCT NAME: RADIUM-223 OG OPLOESELIGE SALTE DERAF, HERUNDER RADIUM-223 DICHLORID; REG. NO/DATE: EU/1/13/873 20131113 |
1140212 | 33/2014 | Austria | ⤷ Sign Up | PRODUCT NAME: RADIUM-223-DICHLORID; REGISTRATION NO/DATE: EU/1/13/873 20131113 |
1140212 | 2014/033 | Ireland | ⤷ Sign Up | PRODUCT NAME: RADIUM-223 AND SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/873 20131113 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |